THERANOSTICS 润色咨询

Theranostics

出版年份：2011 年文章数：3138 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：7.7% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2022-04-26 ms7000000635207998

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向：肿瘤
    经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。

    20

    展开20条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2024-01-10 ms1000000959787142 来自四川省

    感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗

    8

    展开8条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-11-07 ILGN 来自广东省

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享：要求很高了

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-12-26 ms7000000485286504 来自四川省

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-03-14 Judy Bright 来自安徽省

    偏重的研究方向：肺癌;药物治疗
    经验分享：向有投稿经验的人请教一下。
    请问大家这个期刊投稿会显示每一步的投稿状态吗？
    文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？
    而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？

    6

    展开6条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2022-09-11 1811e984f8m

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向：分子生物
    经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。

    10

    展开10条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2022-03-21 ms7000001825764628

    审稿速度:2.0 | 投稿命中率:25.0
    偏重的研究方向：外泌体
    经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？

    5

    展开5条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-05-11 ms6000001741545538 来自韩国

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：疼痛;纳米颗粒;生信
    经验分享：2天拒稿，陈主编建议转投Nanotheranostics。
    我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。
    这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。
    感觉再补几个图还是有戏的，无奈老板的课题到期了。

    6

    展开6条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-12-10 随后 来自湖北省

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1214536, encodeId=97a6121453625, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向：肿瘤<br>经验分享：效率非常高的顶级期刊，一审8天，大修后接收。希望越来越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab816582023, createdName=ms7000000635207998, createdTime=Tue Apr 26 14:15:07 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2180435, encodeId=ce5c2180435aa, content=感觉很快，20多天就给审稿意见，但是！！为啥审稿意见也是所有作者都发呀，这个有点社死，难道不是只给通讯邮件发吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7cb5620202, createdName=ms1000000959787142, createdTime=Wed Jan 10 09:58:55 CST 2024, time=2024-01-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2167292, encodeId=7a80216e2928e, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享：要求很高了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=97, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=ILGN, createdTime=Tue Nov 07 22:49:28 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177349, encodeId=f1db21e734911, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：请教一下大家，期刊大修要求提供WB等的原始图像，是什么形式啊？求救求救~~~~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=74, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02728452887, createdName=ms7000000485286504, createdTime=Tue Dec 26 19:38:12 CST 2023, time=2023-12-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2119377, encodeId=add621193e75f, content=偏重的研究方向：肺癌;药物治疗<br>经验分享：向有投稿经验的人请教一下。<br>请问大家这个期刊投稿会显示每一步的投稿状态吗？<br>文件附件什么的提交之后还是处于可以替换的状态，好几天了，这个是为什么啊？<br>而且当时一提交就是显示Status那里就显示This manuscript is under review. 后面如果审稿了状态会变吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=153, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220323/c7cf4e6998eb4c7b9c22a01d070c1561/eac82b677dd4471abc7021cc1ba93665.jpg, createdBy=a70d6506235, createdName=Judy Bright, createdTime=Tue Mar 14 17:31:10 CST 2023, time=2023-03-14, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=1248422, encodeId=7d3212484228b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向：分子生物<br>经验分享：前年发文量700多篇，去年发文量600余篇，今年预计发文量500篇左右。预计明年IF13分左右。发文量减少，但IF将夜有所提高，预计投稿难度将进一步增加，与中国科研水平进步正相关。肿瘤领域的朋友如果文章被cancer research, 大CDD拒了，可以一试，机会很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=300, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77772040306, createdName=1811e984f8m, createdTime=Sun Sep 11 19:26:50 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204585, encodeId=69cf120458596, content=审稿速度:2.0 | 投稿命中率:25.0<br>偏重的研究方向：外泌体<br>经验分享：请问大家，文章一审一个月左右回来大修，但只有一个审稿人的意见，会不会还有其他意见陆续回来？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=297, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aba65466711, createdName=ms7000001825764628, createdTime=Mon Mar 21 12:10:32 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2131804, encodeId=80cb2131804cd, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：疼痛;纳米颗粒;生信<br>经验分享：2天拒稿，陈主编建议转投Nanotheranostics。<br>我这个稿子6-8分是没有问题的，要在几年前估计还能接受，现在要求高了，投这个也只是想碰碰运气。 <br>这个期刊对格式要求是最少的，也没有对原始数据的要求，感觉造假超容易，在这个分段老被说成水刊也情有可原。<br>感觉再补几个图还是有戏的，无奈老板的课题到期了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=72628668829, createdName=ms6000001741545538, createdTime=Thu May 11 20:26:37 CST 2023, time=2023-05-11, status=1, ipAttribution=韩国), GetPortalCommentsPageByObjectIdResponse(id=2174055, encodeId=3e9721e40556c, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享：2023-11-17投稿，2023-11-30一审结束，速度非常快！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d8ca5307906, createdName=随后, createdTime=Sun Dec 10 15:56:20 CST 2023, time=2023-12-10, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2168842, encodeId=17bb21688420b, content=请问 这个接收阿尔茨海默病的临床文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44ff9063806, createdName=ms4000001858837558, createdTime=Thu Nov 16 14:54:23 CST 2023, time=2023-11-16, status=1, ipAttribution=北京)]
    2023-11-16 ms4000001858837558 来自北京

    请问 这个接收阿尔茨海默病的临床文章吗？

    0

共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分